Clinical Trial Update: Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial sponsored by Novartis is evaluating a targeted lipid optimization program to improve LDL-C control in adults at risk with dyslipidemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Dyslipidemia

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease | Phase 4 | Status: RECRUITING